The present disclosure provides a process for the preparation of compounds of formula (III), ##STR00001##
compounds of formula (V), ##STR00002##
and corresponding salts of formula (IV). ##STR00003## The compounds made by the methods and processes of the invention are particularly useful for administration in humans and animals.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R(I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R(I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

A process for preparing a tin-containing zeolitic material having framework type BEA, comprising providing an aqueous synthesis mixture comprising a boron source, a silicon source, and a BEA structure directing agent; subjecting the synthesis mixture provided in to hydrothermal pre-crystallization conditions; adding the tin source to the obtained mixture; subjecting the obtained aqueous synthesis mixture to hydrothermal crystallization conditions, obtaining a tin-containing zeolitic material having framework type BEA comprised in its mother liquor.

A process for preparing a tin-containing zeolitic material having framework type BEA, comprising providing an aqueous synthesis mixture comprising a boron source, a silicon source, and a BEA structure directing agent; subjecting the synthesis mixture provided in to hydrothermal pre-crystallization conditions; adding the tin source to the obtained mixture; subjecting the obtained aqueous synthesis mixture to hydrothermal crystallization conditions, obtaining a tin-containing zeolitic material having framework type BEA comprised in its mother liquor.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R(I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R(I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

A process for the oxidation of an organic carbonyl compound comprising reacting the compound, optionally in the presence of a solvent, with hydrogen peroxide in the presence of a catalyst comprising a tin-containing zeolitic material and at least one potassium salt.

A process for the oxidation of an organic carbonyl compound comprising reacting the compound, optionally in the presence of a solvent, with hydrogen peroxide in the presence of a catalyst comprising a tin-containing zeolitic material and at least one potassium salt.

A process for forming a flame retardant polymer, as well as the flame retardant polymer, are disclosed. A flame retardant polymer is a polymer that can be resistant to thermal degradation and/or thermal oxidation. A flame retardant polymer can be mixed or otherwise incorporated into a standard polymer to give flame retardancy to the standard polymer. The flame retardant polymers can include polycaprolactone functionalized with flame retardant substituents. The flame retardant substituents can include halides, substituted phosphoryl, and substituted phosphonyl.